Scholarlink

Purpose <p>This systematic review aims to evaluate tumor control outcomes associated with antineoplastic drug therapies used for aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs).</p> Methods <p>We included studies on patients with PC or APT who received one of the following therapies: temozolomide (TMZ), peptide receptor radionuclide therapy (PRRT), everolimus, immune checkpoint inhibitors (ICIs), lapatinib, bevacizumab, capecitabine plus temozolomide (CAPTEM). Search strategies were applied to MEDLINE, EMBASE, LILACS and CENTRAL. Two independent reviewers selected studies, assessed the risk of bias, and extracted data. Proportional meta-analyses were used to calculate overall frequencies of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).</p> Results <p>Seventy eight studies were included. TMZ was the most commonly used therapy, followed by ICIs, bevacizumab, PRRT, CAPTEM, lapatinib, and everolimus. Among 434 patients treated with TMZ in studies involving three or more participants, CR occurred in 4% (95% confidence interval [95% CI], 1–13), PR in 33% (95% CI, 28–37), SD in 32% (95% CI, 28–36), and PD in 29% (95% CI, 25–34). For ICIs, PR occurred in 24% (95% CI, 11–44), SD in 12% (95% CI, 4–31), and PD in 67% (95% CI, 24–93).</p> Conclusion <p>TMZ was the most frequently reported therapy, with PR as the predominant outcome. However, the limited data on ICIs, PRRT, bevacizumab, lapatinib, and everolimus yielded imprecise results, highlighting the need for further research with the aim of gaining more insights into treatment effects of antineoplastic drug therapies for APTs and PCs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年6月2日

查看全文
  • Ana Beatriz Ribeiro Cardoso,
  • Amanda Cristina Zimmermann,
  • Gerald Raverot,
  • Vania dos Santos Nunes-Nogueira

摘要

Purpose

This systematic review aims to evaluate tumor control outcomes associated with antineoplastic drug therapies used for aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs).

Methods

We included studies on patients with PC or APT who received one of the following therapies: temozolomide (TMZ), peptide receptor radionuclide therapy (PRRT), everolimus, immune checkpoint inhibitors (ICIs), lapatinib, bevacizumab, capecitabine plus temozolomide (CAPTEM). Search strategies were applied to MEDLINE, EMBASE, LILACS and CENTRAL. Two independent reviewers selected studies, assessed the risk of bias, and extracted data. Proportional meta-analyses were used to calculate overall frequencies of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).

Results

Seventy eight studies were included. TMZ was the most commonly used therapy, followed by ICIs, bevacizumab, PRRT, CAPTEM, lapatinib, and everolimus. Among 434 patients treated with TMZ in studies involving three or more participants, CR occurred in 4% (95% confidence interval [95% CI], 1–13), PR in 33% (95% CI, 28–37), SD in 32% (95% CI, 28–36), and PD in 29% (95% CI, 25–34). For ICIs, PR occurred in 24% (95% CI, 11–44), SD in 12% (95% CI, 4–31), and PD in 67% (95% CI, 24–93).

Conclusion

TMZ was the most frequently reported therapy, with PR as the predominant outcome. However, the limited data on ICIs, PRRT, bevacizumab, lapatinib, and everolimus yielded imprecise results, highlighting the need for further research with the aim of gaining more insights into treatment effects of antineoplastic drug therapies for APTs and PCs.